Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis

References

• Ballak DB, Stienstra R, Tack CJ, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75:280–290.
   PubMed Web of Science ®Google Scholar
• Sun L, He C, Nair L, et al. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine. 2015;75:249–255.
   PubMed Web of Science ®Google Scholar
• Wakashin H, Hirose K, Iwamoto I, et al. Role of IL-23-Th17 cell axis in allergic airway inflammation. Int Arch Allergy Immunol. 2009;149(Suppl 1):108–112.
   PubMed Web of Science ®Google Scholar
• Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol. 2004;18:31–45.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298–304.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Del Puente A, et al. Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther. 2015;15:1–2.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Costa L, Atteno M, et al. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother. 2013;14:2311–2313.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423–441.
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2007;57:1560–1563.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Atteno M, et al. Simple clinical indicators for early psoriatic arthritis detection. Springerplus. 2014;3:759.
   PubMed Web of Science ®Google Scholar
• Cretu D, Prassas I, Saraon P, et al. Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clin Proteomics. 2014;11:27.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34:1571–1580.
   PubMed Web of Science ®Google Scholar
• van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res Ther. 2014;16:426.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58:61–69.
   PubMed Web of Science ®Google Scholar
• Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl. 2012;89:4–6.
   PubMedGoogle Scholar
• Scarpa R, Ayala F, Caporaso N, et al. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006;33:210–212.
   PubMed Web of Science ®Google Scholar
• Duarte GV, Faillace C, Freire De Carvalho J. Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26:147–156.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Manguso F, D’Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27:1241–1246.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Khalid U, Gislason GH, et al. Association of psoriatic disease with uveitis: A Danish Nationwide cohort study. JAMA Dermatol. 2015. DOI:10.1001/jamadermatol.2015.1986.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31:711–715.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61:147–153.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38:373–386.
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol. 2012;39:849–855.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39:154–156.
   PubMed Web of Science ®Google Scholar
• Cervini C, Leardini G, Mathieu A, et al. Psoriatic arthritis: epidemiological and clinical aspects in a cohort of 1.306 Italian patients. Reumatismo. 2005;57:283–290.
   PubMedGoogle Scholar
• Pasquetti P, Morozzi G, Galeazzi M. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology (Oxford). 2009;48:315–316.
   PubMed Web of Science ®Google Scholar
• Popescu C, Zofotă S, Bojincă V, et al. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis–cross-sectional study and literature review. J Med Life. 2013;6:376–382.
   PubMedGoogle Scholar
• Schellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155–163.
   PubMed Web of Science ®Google Scholar
• Nijenhuis S, Zendman AJ, Vossenaar ER, et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta. 2004;350:17–34.
   PubMed Web of Science ®Google Scholar
• Perez-Alamino R, Garcia-Valladares I, Cuchacovich R, et al. Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?. Rheumatol Int. 2014;34:1211–1216.
   PubMed Web of Science ®Google Scholar
• Acosta Felquer ML, Ferreyra Garrott L, Marin J, et al. Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol. 2014;33:1323–1330.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Stramare R, Coran A, et al. Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol. 2015. DOI:10.1007/s10067-015-2894-1.
   Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine. 2013;80:165–170.
   PubMed Web of Science ®Google Scholar
• Soscia E, Sirignano C, Catalano O, et al. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl. 2012;89:49–53.
   PubMedGoogle Scholar
• Tan AL, Fukuba E, Halliday NA, et al. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis. 2015;74:185–189.
   PubMed Web of Science ®Google Scholar
• Poggenborg RP, Eshed I, Østergaard M, et al. Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by ‘head-to-toe’ whole-body MRI and clinical examination. Ann Rheum Dis. 2015;74:823–829.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551–1557.
   PubMed Web of Science ®Google Scholar
• Goodman WA, Levine AD, Massari JV, et al. IL-6signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009;183:3170–3176.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther. 2010;12:R148.
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717–1725.
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004;15:353–366.
   PubMed Web of Science ®Google Scholar
• Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121–136.
   PubMed Web of Science ®Google Scholar
• Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14:185–191.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12:599–606.
   PubMed Web of Science ®Google Scholar
• Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. J Rheumatol. 2014;41:1237–1239.
   PubMed Web of Science ®Google Scholar
• Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71:319–326.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al.; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.
   PubMed Web of Science ®Google Scholar
• Lemos LL, De Oliveira Costa J, Almeida AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34:1345–1360.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000;59:428–433.
   PubMed Web of Science ®Google Scholar
• Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002;47:506–512.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, De Vlam K, et al.; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, et al.; IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498–505.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56:2698–2707.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869–876.
   PubMed Web of Science ®Google Scholar
• Hoff M, Kavanaugh A, Haugeberg G. Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. J Rheumatol. 2013;40:1344–1348.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis. 2006;65:471–477.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006;33:2254–2259.
   PubMed Web of Science ®Google Scholar
• Voulgari PV, Venetsanopoulou AI, Exarchou SA, et al. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin Arthritis Rheum. 2008;37:293–298.
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayová H, Kungurov NV, et al.; RESPOND investigators. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541–548.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007;66:778–781.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Woolley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol. 2010;37:1221–1227.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. Bmj. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• FitzGerald O, Helliwell P, Mease P, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71:358–362.
   PubMed Web of Science ®Google Scholar
• Kirkham B, De Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. 2015;33:11–19.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Sterry W, Brock F, et al. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. Br J Dermatol. 2015;172:230–238.
   PubMed Web of Science ®Google Scholar
• Boggs RL, Kárpáti S, Li W, et al. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. BMC Dermatol. 2014;14:14.
   PubMedGoogle Scholar
• Gniadecki R, Robertson D, Molta CT, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol. 2012;26:1436–1443.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17:343–352.
   PubMed Web of Science ®Google Scholar
• Frankel EH, Strober BE, Crowley JJ, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis. 2007;79:322–326.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jackson JM, Sobell JM, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol. 2007;6:299–306.
   PubMedGoogle Scholar
• Lubrano E, Spadaro A, Marchesoni A, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol. 2011;29:80–84.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Bombardier C, Thorne C, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol. 2011;38:1355–1362.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–488.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Heckaman M, Kary S, et al. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT. J Rheumatol. 2013;40:647–652.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12:R113.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702–709.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT, et al.; M02-570 Study Group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040–1050.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, Gerlag DM, Vos K, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009;68:1303–1309.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Sampalis JS, Illouz O, et al.; ACCLAIM Study Investigators. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37:1898–1906.
   PubMed Web of Science ®Google Scholar
• Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466–2474.
   PubMed Web of Science ®Google Scholar
• Poggenborg RP, Wiell C, Bøyesen P, et al. No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology. 2014;53:746–756.
   PubMed Web of Science ®Google Scholar
• Poggenborg RP, Bird P, Boonen A, et al. Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy. Scand J Rheumatol. 2014;43:202–208.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504–2517.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013;72:1777–1785.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;65:1666–1673.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689–1694.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.
   PubMed Web of Science ®Google Scholar
• Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken). 2014;66:1085–1092.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2015;74:44–51.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233–237.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol. 2011;30:1063–1067.
   PubMed Web of Science ®Google Scholar
• Eder L, Thavaneswaran A, Chandran V, et al. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014;73:1007–1011.
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883–890.
   PubMed Web of Science ®Google Scholar
• Fransen J, Antoni C, Mease PJ, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006;65:1373–1378.
   PubMed Web of Science ®Google Scholar
• Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. Scand J Rheumatol. 2008;37:399–400.
   PubMed Web of Science ®Google Scholar
• Braun-Moscovici Y, Markovits D, Rozin A, et al. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J. 2008;10:277–281.
   PubMed Web of Science ®Google Scholar
• Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010;29:399–403.
   PubMed Web of Science ®Google Scholar
• Migliore A, Bizzi E, Broccoli S, et al. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol. 2012;31:133–137.
   PubMed Web of Science ®Google Scholar
• Saougou I, Markatseli TE, Papagoras C, et al. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum. 2011;40:398–406.
   PubMed Web of Science ®Google Scholar
• Martinez-Cutillas J, Alerany-Pardo C, Borrás-Blasco J, et al. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Expert Rev Pharmacoecon Outcomes Res. 2015;14:1–8.
   Google Scholar
• Gladman DD. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. Nat Clin Pract Rheumatol. 2008;4:510–511.
   PubMedGoogle Scholar
• Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014;73:132–137.
   PubMed Web of Science ®Google Scholar
• Soubrier AS, Bele-Philippe P, Cortet B, et al. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year “real life” experience. Joint Bone Spine. 2015;82:31–37.
   PubMed Web of Science ®Google Scholar
• Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Gudbjornsson B, Krogh NS, et al. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. Rheumatology (Oxford). 2014;53:2100–2109.
   PubMed Web of Science ®Google Scholar
• Behrens F, Cañete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford). 2015;54:915–926.
   PubMed Web of Science ®Google Scholar
• Nannini C, Cantini F, Niccoli L, et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?. Arthritis Rheum. 2009;61:801–812.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–1050.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics. 2012;6:417–427.
   PubMedGoogle Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524.
   PubMed Web of Science ®Google Scholar
• Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66:1472–1481.
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, et al.; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49:697–705.
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–408.
   PubMed Web of Science ®Google Scholar
• Hellgren K, Smedby KE, Backlin C, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol. 2014;66:1282–1290.
   PubMed Web of Science ®Google Scholar
• Carmona L, Abasolo L, Descalzo MA, et al.; BIOBADASER Study Group. EMECAR Study Group. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011;41:71–80.
   PubMed Web of Science ®Google Scholar
• Ventura-Ríos L, Bañuelos-Ramírez D, Hernández-Quiroz Mdel C, et al. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatol Clin. 2012;8:189–194.
   PubMedGoogle Scholar
• Caso F, Cantarini L, Morisco F, et al Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther. 2015;15:641–650.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014;33:273–276.
   PubMed Web of Science ®Google Scholar
• Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28:846–852.
   PubMed Web of Science ®Google Scholar
• Jung SM, Ju JH, Park MS, et al. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int J Rheum Dis. 2015;18:323–330.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford). 2014;53:1477–1481.
   PubMed Web of Science ®Google Scholar
• Atteno M, Costa L, Matarese A, et al. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol. 2014;33:543–547.
   PubMed Web of Science ®Google Scholar
• Mongey AB, Doran JP, Kleinerova J, et al. Late onset tuberculosis infection in patients receiving anti-TNFα therapy. Qjm. 2014;107:69–71.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Salhotra A, Fleisher J, et al. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?. J Infect. 2010;60:386–396.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009;36:2416–2420.
   PubMed Web of Science ®Google Scholar
• Jani M, Macphie E, Rao C, et al. Effectiveness of switching between biologics in psoriatic arthritis- results of a large regional survey. Clin Med. 2014;14:95–96.
   PubMed Web of Science ®Google Scholar
• Ohshima Y, Kinoshita Y, Akita Y, et al. Psoriatic arthritis that responded dramatically when infliximab was switched to adalimumab. Ann Dermatol. 2013;25:496–497.
   PubMed Web of Science ®Google Scholar
• Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr. 2010;160:220–224.
   PubMedGoogle Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al.; PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–999.
   PubMed Web of Science ®Google Scholar
• Ogata A, Umegaki N, Katayama I, et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 2012;79:85–87.
   PubMed Web of Science ®Google Scholar
• Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford). 2013;52:1728–1729.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Cantarini L, et al. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol. 2014;33:1355–1357.
   PubMed Web of Science ®Google Scholar
• Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol. 2010;29:1169–1173.
   PubMed Web of Science ®Google Scholar
• Mazur M, Karczewski J, Lodyga M, et al. Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis. J Dermatolog Treat. 2015;26:326–328.
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?. Expert Opin Biol Ther. 2013;13:1673–1682.
   PubMed Web of Science ®Google Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435.
   PubMed Web of Science ®Google Scholar
• Zisapel M, Zisman D, Madar-Balakirski N, et al. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42:73–78.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:1074–1080.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2009;39:157–162.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131–1135.
   PubMed Web of Science ®Google Scholar
• Shang Q, Tam LS, Sanderson JE, et al. Impaired left ventricular apical rotation is associated with disease activity of psoriatic arthritis. J Rheumatol. 2014;41:706–713.
   PubMed Web of Science ®Google Scholar
• Shen J, Shang Q, Li EK, et al. Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther. 2015;17:75.
   PubMed Web of Science ®Google Scholar
• Dalal DS, Lin YC, Brennan DM, et al. Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS). Semin Arthritis Rheum. 2015;44:641–645.
   PubMed Web of Science ®Google Scholar
• Da Silva BS, Bonfá E, De Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010;38:567–569.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33:833–839.
   PubMed Web of Science ®Google Scholar
• Ramonda R, Puato M, Punzi L, et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine. 2014;81:421–425.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306:864–871.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013:513782.
   PubMedGoogle Scholar
• Scarpa R. Is it time to leave the family?. Arthritis Rheumatol. 2015. DOI:10.1002/art.39303.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015. DOI:10.1038/nrrheum.2015.86.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Del Puente A, et al. Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis. 2015 Sep. DOI:10.1177/2040622315608647.
   PubMed Web of Science ®Google Scholar
• Sweeney CM, Tobin AM, Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res. 2011;303:691–705.
   PubMed Web of Science ®Google Scholar
• Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–833.
   PubMed Web of Science ®Google Scholar
• Schön MP. Animal models of psoriasis: a critical appraisal. Exp Dermatol. 2008;17:703–712.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang G, Zhang J, et al. Anti-TNF-α monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol. 2015;28(1):731–743.
   PubMed Web of Science ®Google Scholar